{"id":"candsartan-cilexetil","_chembl":{"chemblId":"CHEMBL2104038","moleculeType":"Small molecule","molecularWeight":"186.25"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Angiotensin II Type 1 (AT1) receptor","explanation":"Candesartan cilexetil is a prodrug that is rapidly converted to its active form, candesartan, during absorption. Candesartan selectively blocks AT1 receptors, preventing angiotensin II from binding and causing vasoconstriction, aldosterone secretion, and sympathetic activation, resulting in decreased blood pressure and reduced cardiovascular strain.","oneSentence":"Blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure."},"_scrapedAt":"2026-03-28T01:04:46.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122656,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"losartan","brand":"Cozaar","company":"Merck","rationale":"First-in-class ARB for hypertension and heart failure"},{"name":"valsartan","brand":"Diovan","company":"Novartis","rationale":"ARB for hypertension and heart failure"},{"name":"irbesartan","brand":"Avapro","company":"Sanofi","rationale":"ARB for hypertension with similar mechanism"}],"description":"Candesartan cilexetil is an angiotensin II receptor blocker (ARB) developed by AstraZeneca for the treatment of hypertension and heart failure. It works by blocking the AT1 receptor, preventing vasoconstriction and aldosterone secretion, thereby lowering blood pressure and reducing cardiac workload.","indications":{"approved":[{"status":"investigational","condition":"Hypertension","patientPopulation":"Adult"},{"status":"investigational","condition":"Heart failure","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT00244595","phase":"PHASE3","title":"Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Hypertension","enrollment":235},{"nctId":"NCT00244634","phase":"PHASE3","title":"Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Pediatric Hypertension","enrollment":238}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"SYNCOPE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"candsartan cilexetil","genericName":"candsartan cilexetil","companyName":"AstraZeneca","companyId":"astrazeneca","firstApprovalDate":"","aiSummary":"Candesartan cilexetil is a small molecule used to treat hypertension and pediatric hypertension. It is administered as part of a clinical study to evaluate its efficacy, safety, and pharmacokinetics in hypertensive pediatric subjects aged 6 to 17 years.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}